Global Dermatology Market to 2022 - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth

GBI Research
144 Pages - GBI10524
$4,995.00

Summary

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition.For the past decades, the majority of the dermatology market has remained saturated with established products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.

This report covers all dermatological disorders, but there is a particular focus on three key diseases: atopic dermatitis, acne vulgaris and psoriasis, as these conditions have the highest prevalence and the largest pipeline. The global dermatology market was valued at $20.0 billion in 2015, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 7.73%, reaching $33.7 billion in 2022. Key drivers of this growth will be the uptake of recently approved premium biologics, as well as promising late-stage products that are expected to be highly valuable.

Scope

The dermatology market landscape is expected to change substantially with the advent of promising novel pipeline products.
Overall, there are 801 dermatology products in the pipeline, with biologics representing 37% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.
 - Which molecular targets are most prominent within the pipeline?
 - How do the key indications differ in terms of molecule type?
 - How does the composition of the pipeline compare with that of the existing market?
 - What mechanisms of action are most common for pipeline drugs?
Global revenues for the dermatology market are forecast to grow at a CAGR of 7.73%, from $20 billion in 2015 to $33.7 billion in 2022.
 - Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
 - Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
 - What CAGR will these companies register in the forecast period?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis.
- Visualize the composition of the dermatology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
- Analyze the dermatology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications.
- Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
- Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various dermatological conditions.
- Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.

'

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 10
2.1 Therapy Area Introduction 10
2.2 Symptoms 10
2.3 Etiology and Pathophysiology 11
2.3.1 Atopic Dermatitis 11
2.3.2 Acne Vulgaris 12
2.3.3 Psoriasis 13
2.4 Co-morbidities and Complications 14
2.5 Epidemiology Patterns and Forecasts - Prevalence and Patient Segmentation 14
2.5.1 Atopic Dermatitis 15
2.5.2 Acne Vulgaris 16
2.5.3 Psoriasis 16
2.6 Treatment 17
2.6.1 Topical Corticosteroids 18
2.6.2 Calcineurin Inhibitors 19
2.6.3 Retinoids 19
2.6.4 Systemic Immunosuppressive Agents 20
2.6.5 Biologics 20
2.6.6 Antihistamines 21
2.6.7 Hormonal Therapy 21
2.6.8 Moisturizers 21
3 Key Marketed Products 23
3.1 Overview 23
3.2 Humira (adalimumab) 24
3.3 Remicade (infliximab) 26
3.4 Enbrel (etanercept) 27
3.5 Stelara (ustekinumab) 29
3.6 Neoral (cyclosporine) 30
3.7 Protopic (tacrolimus) 32
3.8 Elidel (pimecrolimus) 33
3.9 Elocon (mometasone furoate) 34
3.10 Differin (adapalene) 35
3.11 Metolate (methotrexate) 36
3.12 Clobex (clobetasol propionate) 36
3.13 Conclusion 37
4 Pipeline Landscape Assessment 38
4.1 Overview 38
4.2 Molecule Types in the Pipeline 41
4.3 Molecular Targets in the Pipeline 43
4.4 Clinical Trials 44
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 45
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 48
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 52
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 56
4.5 Conclusion 61
5 Multi-Scenario Market Forecast to 2022 62
5.1 Overall Market Size 62
5.2 Generic Penetration 63
5.3 Revenue Forecast by Molecular Target 65
5.3.1 Tumor Necrosis Factor-Alpha 65
5.3.2 Interleukins 1, 4, 5, 12, 17 and 23 and Receptors 66
5.3.3 Calcineurin 67
5.3.4 Glucocorticoid Receptors 68
5.3.5 Phosphodiesterase 4 69
5.3.6 Revenue and Market Share Analysis by Company 70
5.3.7 Assessment of Key Pipeline Products 80
6 Company Analysis and Positioning 88
6.1 Company Landscape 89
6.2 Marketed and Pipeline Portfolio Analysis 90
7 Strategic Consolidations 93
7.1 Licensing Deals 93
7.1.1 Deals by Region, Year and Value 93
7.1.2 Deals by Stage of Development and Value 95
7.1.3 Deals by Molecule Type, Mechanism of Action and Value 96
7.1.4 Table for Licensing Deals Valued Above $100m 98
7.2 Co-development Deals 99
7.2.1 Deals by Region, Year and Value 99
7.2.2 Deals by Stage of Development and Value 100
7.2.3 Deals by Molecule Type, Mechanism of Action and Value 101
7.2.4 Table for Co-development Deals Valued Above $100m 103
8 Appendix 104
8.1 References 104
8.2 Table of Epidemiology Forecast 109
8.3 Table of All Clinical Stage Pipeline Products 110
8.4 Abbreviations 141
8.5 Disease List 142
8.6 Methodology 142
8.6.1 Coverage 142
8.6.2 Secondary Research 142
8.6.3 Market Size and Revenue Forecasts 143
8.6.4 Pipeline Analysis 143
8.6.5 Competitive Landscape 143
8.7 Contact Us 144
8.8 Disclaimer 144

1.1 List of Tables
Table 1: Dermatology, Global, Epidemiology of Dermatological Disorders, 2015 15
Table 2: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Humira, 2015 25
Table 3: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Remicade, 2015 26
Table 4: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Enbrel, 2015 28
Table 5: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Stelara, 2015 29
Table 6: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Neoral, 2015 31
Table 7: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Protopic, 2015 32
Table 8: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elidel, 2015 34
Table 9: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Elocon, 2015 34
Table 10: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Differin, 2015 35
Table 11: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Metolate, 2015 36
Table 12: Dermatology Therapeutics Market, Global, Approved Dermatology Indications for Clobex, 2015 37
Table 13: Dermatology Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($bn), 2015-2022 63
Table 14: Dermatology, Global, Usage of Generics Across Key Indications, 2015 65
Table 15: Dermatology Therapeutics Market, Global, Forecast Revenue by Company, 2015-2022 70
Table 16: Dermatology Therapeutics Market, Global, Licensing Deals, 2006-2016 98
Table 17: Dermatology Therapeutics Market, Global, Co-development Deals, 2006-2016 103
Table 18: Epidemiology Patterns for Atopic Dermatitis, 2015-2022 109
Table 19: Epidemiology Patterns for Acne Vulgaris, 2015-2022 109
Table 20: Epidemiology Patterns for Psoriasis, 2015-2022 109
Table 21: Dermatology, Global, Table of all Clinical Stage Pipeline Products, 2016 110
Table 22: Abbreviations 141

1.2 List of Figures
Figure 1: Epidemiology Patterns for Atopic Dermatitis (Million), 2015-2022 15
Figure 2: Epidemiology Patterns for Acne Vulgaris (Million), 2015-2022 16
Figure 3: Epidemiology Patterns for Psoriasis (Million), 2015-2022 17
Figure 4: Dermatology, Global, Key Marketed Products and Approved Indications, 2015 24
Figure 5: Dermatology Therapeutics Market, Global, Annual Revenue for Humira ($bn), 2006-2022 26
Figure 6: Dermatology Therapeutics Market, Global, Annual Revenue for Remicade ($bn), 2006-2022 27
Figure 7: Dermatology Therapeutics Market, Global, Annual Revenue for Enbrel ($bn), 2006-2022 29
Figure 8: Dermatology Therapeutics Market, Global, Annual Revenue for Stelara ($bn), 2010-2022 30
Figure 9: Dermatology Therapeutics Market, Global, Annual Revenue for Neoral ($m), 2006-2022 32
Figure 10: Dermatology Therapeutics Market, Global, Annual Revenue for Protopic ($m), 2006-2022 33
Figure 11: Dermatology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016 38
Figure 12: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Stage of Development, Molecule Type and Program Type, 2016 40
Figure 13: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Stage of Development, 2016 41
Figure 14: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecule Type, 2016 42
Figure 15: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Molecular Target, 2016 43
Figure 16: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecular Target, 2016 44
Figure 17: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016 45
Figure 18: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016 46
Figure 19: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016 47
Figure 20: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016 48
Figure 21: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016 49
Figure 22: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016 50
Figure 23: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016 51
Figure 24: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016 52
Figure 25: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2016 53
Figure 26: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016 54
Figure 27: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016 55
Figure 28: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016 56
Figure 29: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2016 57
Figure 30: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016 58
Figure 31: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016 59
Figure 32: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016 60
Figure 33: Dermatology Global, Market Size ($bn), 2015-2022 62
Figure 34: Dermatology Global, Annual Revenue Forecast for Key Products ($bn), 2015-2022 64
Figure 35: Dermatology, Global, Annual Revenue Forecast for Tumor Necrosis Factor-Alpha Inhibitors ($bn), 2015-2022 66
Figure 36: Dermatology, Global, Annual Revenue Forecast for Interleukin Inhibitors ($bn), 2015-2022 67
Figure 37: Dermatology, Global, Annual Revenue Forecast for Calcineurin Inhibitors ($bn), 2015-2022 68
Figure 38: Dermatology, Global, Annual Revenue Forecast for Glucocorticosteroids ($m), 2015-2022 69
Figure 39: Dermatology, Global, Annual Revenue Forecast for Phosphodiesterase 4 inhibitors ($bn), 2015-2022 69
Figure 40: Dermatology Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022 72
Figure 41: Dermatology, Global, Companies by Compound Annual Growth Rate (%), 2015-2022 73
Figure 42: Dermatology, Global, Revenues by Product Type, 2015-2022 74
Figure 43: Dermatology, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015-2022 75
Figure 44: Dermatology, Global, AbbVie Annual Revenue Forecast ($bn), 2015-2022 76
Figure 45: Dermatology, Global, Amgen Annual Revenue Forecast ($bn), 2015-2022 77
Figure 46: Dermatology, Global, Novartis Annual Revenue Forecast ($bn), 2015-2022 78
Figure 47: Dermatology, Global, Roche Annual Revenue Forecast ($bn), 2015-2022 79
Figure 48: Dermatology, Global, Merck Annual Revenue Forecast ($bn), 2015-2022 80
Figure 49: Dermatology Therapeutics Market, Global, Revenue Forecast for ABP-501 ($m), 2015-2022 81
Figure 50: Dermatology Therapeutics Market, Global, Revenue Forecast for ixekizumab ($m), 2016-2022 82
Figure 51: Dermatology Therapeutics Market, Global, Revenue Forecast for dupilumab ($m), 2016-2022 83
Figure 52: Dermatology Therapeutics Market, Global, Revenue Forecast for AN-2728 ($m), 2016-2022 84
Figure 53: Dermatology Therapeutics Market, Global, Revenue Forecast for AMG-827 ($m), 2016-2022 85
Figure 54: Dermatology Therapeutics Market, Global, Revenue Forecast for guselkumab ($m), 2016-2022 86
Figure 55: Dermatology Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022 88
Figure 56: Dermatology, Global, Companies by Type, 2016 90
Figure 57: Dermatology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Dermatology Specialization, 2016 91
Figure 58: Dermatology, Global, Proportion of Total Company Revenue Attributed to Dermatology, 2015-2022 92
Figure 59: Dermatology, Global, Licensing Deals, 2006-2016 94
Figure 60: Dermatology, Global, Licensing Deals by Indication, 2006-2016 95
Figure 61: Dermatology, Global, Licensing Deals, 2006-2016 96
Figure 62: Dermatology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016 97
Figure 63: Dermatology, Global, Co-development Deals, 2006-2016 99
Figure 64: Dermatology, Global, Co-development Deals by Indication, 2006-2016 100
Figure 65: Dermatology, Global, Co-development Deals, 2006-2016 101
Figure 66: Dermatology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016 102

$4,995.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports